We constantly work to develop clinically relevant models to provide reliable platforms for preclinical drug validation.
Today, we are thrilled to announce the launch of our second segment model on human breast cancer, using orthotopic transplantation of patient-derived xenografts (PDX) and in vivo bioluminescence imaging. All of these essential components are conducted in-house, ensuring seamless integration and efficient execution.
To access our breast cancer segment model and gain valuable insights into human breast cancer research, please download here.
If you have any questions or would like to explore how our expertise can support the next steps in your preclinical pipeline, please don't hesitate to contact us at firstname.lastname@example.org. We look forward to assisting you in advancing breast cancer research and drug development.